111 related articles for article (PubMed ID: 29970342)
41. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
42. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.
Barosi G; Massa M; Campanelli R; Fois G; Catarsi P; Viarengo G; Villani L; Poletto V; Bosoni T; Magrini U; Gale RP; Rosti V
Leuk Res; 2017 Sep; 60():18-23. PubMed ID: 28622624
[TBL] [Abstract][Full Text] [Related]
43. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
[TBL] [Abstract][Full Text] [Related]
44. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Xu Q; Li Y; Lv N; Jing Y; Xu Y; Li Y; Li W; Yao Z; Chen X; Huang S; Wang L; Li Y; Yu L
Clin Cancer Res; 2017 Aug; 23(15):4511-4522. PubMed ID: 28246275
[No Abstract] [Full Text] [Related]
45. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
46. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
47. Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.
Beauverd Y; Alimam S; McLornan DP; Radia DH; Harrison CN
Br J Haematol; 2016 Oct; 175(1):37-42. PubMed ID: 27293069
[TBL] [Abstract][Full Text] [Related]
48. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
Jawhar M; Schwaab J; Schnittger S; Meggendorfer M; Pfirrmann M; Sotlar K; Horny HP; Metzgeroth G; Kluger S; Naumann N; Haferlach C; Haferlach T; Valent P; Hofmann WK; Fabarius A; Cross NC; Reiter A
Leukemia; 2016 Jan; 30(1):136-43. PubMed ID: 26464169
[TBL] [Abstract][Full Text] [Related]
49. Generation and characterization of a human induced pluripotent stem (iPS) cell line derived from an acute myeloid leukemia patient evolving from primary myelofibrosis carrying the CALR 52bp deletion and the ASXL1 p.R693X mutation.
Gomez Limia CE; Devalle S; Reis M; Sochacki J; Carneiro M; Madeiro da Costa R; D'Andrea M; Padilha T; Zalcberg IR; Solza C; Daumas A; Rehen S; Monte-Mór B; Bonamino MH
Stem Cell Res; 2017 Oct; 24():16-20. PubMed ID: 29034885
[TBL] [Abstract][Full Text] [Related]
50. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
[TBL] [Abstract][Full Text] [Related]
51. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
52. [New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
[TBL] [Abstract][Full Text] [Related]
53. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e151-6. PubMed ID: 26566925
[TBL] [Abstract][Full Text] [Related]
54. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
[TBL] [Abstract][Full Text] [Related]
55. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
56. Spectrum of
Rotunno G; Mannarelli C; Brogi G; Pacilli A; Gesullo F; Mannelli F; Fiaccabrino S; Sordi B; Paoli C; Marone I; Rumi E; Manfredini R; Barosi G; Cazzola M; Vannucchi AM; Guglielmelli P
Blood; 2019 Jun; 133(26):2802-2808. PubMed ID: 31076447
[No Abstract] [Full Text] [Related]
57. SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis.
Lehmann U; Bartels S; Hasemeier B; Geffers R; Schlue J; Büsche G; Hussein K; Kreipe H
Blood; 2013 May; 121(19):4011-2. PubMed ID: 23660863
[No Abstract] [Full Text] [Related]
58. [A case of prefibrotic primary myelofibrosis in a child with type-Ⅰ CALR gene mutation].
Li SQ; Zhao YQ; Zhao XL; Wang XG; Li SB; Song LL; Zhou YJ; Zang WT; Hao T; Yao XJ
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):928-930. PubMed ID: 37803861
[TBL] [Abstract][Full Text] [Related]
59. Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.
Yan X; Xu Z; Zhang P; Sun Q; Jia Y; Qin T; Qu S; Pan L; Li Z; Liu J; Song Z; Gao Q; Jiao M; Gong J; Wang H; Li B; Xiao Z
Blood Cancer J; 2023 Apr; 13(1):56. PubMed ID: 37080954
[No Abstract] [Full Text] [Related]
60. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
